<DOC>
	<DOCNO>NCT02483247</DOCNO>
	<brief_summary>This open label , multi-center , Phase 1/2 study BBI503 administer combination select anti-cancer therapeutic adult patient advance cancer . The goal study determine safety , tolerability , RP2D BBI503 combination select anti-cancer agent .</brief_summary>
	<brief_title>A Study BBI503 Combination With Selected Anti-Cancer Therapeutics Adult Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<criteria>Major inclusion criterion : 1 . A histologically cytologically confirm solid tumor locally advance , recurrent , metastatic ; curative resection currently possible ; systemic treatment one select anticancer agent reasonable therapeutic option . 2 . Must ≥ 18 year age 3 . Has disease progression response therapy evaluate objectively protocol . 4 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 5 . Male female patient childbearing potential must agree use contraception avoidance pregnancy measure study 30 day last dose . 6 . Females childbearing potential must negative serum pregnancy test . 7 . Must aspartate transaminase ( AST ) ≤ 2.5 × upper limit normal ( ULN ) alanine transaminase ( ALT ) ≤ 2.5 × ULN . Patients hepatocellular carcinoma liver lesion liver metastasis may eligible AST ≤ 3.5 × ULN AST ≤ 3.5 × ULN agree upon investigator medical monitor sponsor . 8 . Hemoglobin ( Hgb ) ≥ 9 g/dl 9 . Total bilirubin ≤ 1.5 × ULN . For patient liver lesion , total bilirubin ≤ 2.0 × ULN may enrol agree upon investigator medical monitor sponsor 10 . Creatinine ≤ 1.5 × ULN creatinine clearance ≥ 60 mL/min/1.73 m^2 patient creatinine level institutional upper limit normal ( use CockcroftGault equation ) . 11 . Absolute neutrophil count ≥ 1.5 × 10^9/L 12 . Platelets ≥ 100 × 10^9/L 13 . Life expectancy ≥ 3 month Major exclusion criterion : 1 . Received anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose protocol therapy . Patients may begin protocol therapy date determine investigator medical monitor sponsor minimum 7 day since last receiving anticancer treatment , provide adverse event relate resolve deem irreversible . 2 . Major surgery within 4 week prior first dose ; major surgery define procedure require follow : general anesthesia , intubation mechanical ventilation , major incision ( e.g. , thoracotomy , laparotomy ) 3 . Any known , untreated , brain metastasis . Patients treat brain metastasis must clinical symptom metastasis , must either steroid stable dose steroid ≤ 10 mg prednisone equivalent least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . 4 . Pregnant breastfeeding expect conceive father child within project duration study . 5 . Significant gastrointestinal disorder ( ) , opinion Principal Investigator , active inflammatory bowel disease , extensive gastric small intestinal resection ( resulted shortgut syndrome inability take oral medication ) . 6 . Unable unwilling swallow either BBI503 daily oral select anticancer therapeutic ; , unwilling receive intravenous injection IV anticancer therapeutic . 7 . Positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( Hepatitis B Surface Antigen [ HBsAg ] reactive ) , Hepatitis C virus ( Hepatitis C Virus Ribonucleic Acid ( HCV RNA ] ( qualitative ) detect ) . 8 . Uncontrolled concurrent illness include , limited : ongoing active infection require therapy , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement 9 . Subjects history another primary cancer exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) localize prostate cancer require systematic therapy ; ) primary cancer know active disease present , treatment administer 2 year prior enrollment . 10 . For patient treated regimen contain capecitabine : ) Known hypersensitivity capecitabine , b ) Known dihydropyrimidine dehydrogenase ( DPD ) deficiency , c ) Significant gastrointestinal disorder ( ) would , opinion Investigator , prevent absorption orally available agent 11 . For patient treated regimen contain sunitinib : ) Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) , b ) Evidence bleed diathesis clinically significant coagulopathy ( ≥ CTCAE Grade 3 ) within 4 week prior start study , c ) Recent hypoglycemia , ) Uncontrolled thyroid dysfunction despite optimal medical therapy 12 . For patient treated regimen contain doxorubicin : ) Known leave ventricular ejection fraction &lt; 50 % , b ) Hypersensitivity doxorubicin 13 . A patient treat regimen contain nivolumab pembrolizumab exclude patient : ) Has active autoimmune disease require immunosuppression exception subject isolate vitiligo , resolve childhood asthma atopic dermatitis , control hypoadrenalism hypopituitarism , euthyroid patient history Grave 's disease , b ) Has previous lifethreatening ( CTCAE grade 4 ) immunemediated adverse reaction ; , previous severe ( CTCAE grade 3 ) immune mediate adverse reaction require treatment corticosteroid ( 10 mg/day prednisone equivalent dose ) longer 12 week , c ) Has transplant organ , ) Has interstitial lung disease active , noninfectious pneumonitis , e ) Has receive live vaccine within 30 day prior first dose , f ) Previous severe hypersensitivity reaction another monoclonal antibody ( mAb ) , g ) Has treat another monoclonal antibody ≤ 4 week first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
</DOC>